

Health Care: Drugs
Cypress Biosciences Inc. (CYPB: NASDAQ)
$6.50 0.01 | 0.15%
01/13/11 - 04:00 PM ET
140.78K / 727.00K
Vol / Avg. Vol:
6.50 / 6.49
Open / Prev. Close:
6.49 - 6.50
Today's Range:
Portfolios with CYPB
Latest CYPB Headlines from TheStreet
More Financial News for CYPB
Press Releases for CYPB
- Cypress Bioscience, Inc. Shareholder Investigation By Briscoe Law Firm Concerning Acquisition By Ramius V&O Acquisition, LLC - Business Wire 12.20.10 | 12:12 pm
- The Law Office Of Abe Shainberg Launches An Investigation Into The Possible Breaches Of Fiduciary Duty By The Board Of Cypress Bioscience, Inc. In Connection With The Sale Of Company To Ramius V & O Acquisition, LLC– CYPB - Business Wire 12.17.10 | 01:12 pm
- The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into The Possible Breaches Of Fiduciary Duty By The Board Of Cypress Bioscience, Inc. In Connection With The Sale Of Company To Ramius V & O Acquisition, LLC– CYPB - Business Wire 12.16.10 | 11:12 am
- The Law Firm Of Weiss & Lurie Investigates The Acquisition Of Cypress Bioscience, Inc. By Ramius V&O Acquisition LLC And Royalty Pharma - Business Wire 12.15.10 | 02:12 pm
- Cypress Bioscience Agrees To Be Acquired By Ramius LLC And Royalty Pharma For $6.50 Per Share In Cash - Business Wire 12.15.10 | 08:12 am
- Cypress Bioscience Board Of Directors Confirms Receipt Of Revised Ramius LLC Offer In Connection With Strategic Review Process - Business Wire 12.10.10 | 11:12 am
- Alexza's Staccato® Nicotine Licensed To Cypress Bioscience - PR Newswire 08.26.10 | 08:08 am
- Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Shareholders Of Cypress Bioscience, Inc. - Business Wire 07.21.10 | 09:07 pm
- Kendall Law Group Investigates Cypress Bioscience, Inc. Acquisition For Shareholders - Business Wire 07.20.10 | 03:07 pm
- Rigrodsky & Long, P.A. Investigates Cypress Bioscience, Inc. Going Private Offer - Business Wire 07.20.10 | 11:07 am
See All Press Releases
Partner Headlines for CYPB